Nuance Investments LLC Sells 31,921 Shares of Henry Schein, Inc. $HSIC

Nuance Investments LLC lowered its position in Henry Schein, Inc. (NASDAQ:HSIC) by 10.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 282,287 shares of the company’s stock after selling 31,921 shares during the period. Henry Schein makes up 2.4% of Nuance Investments LLC’s investment portfolio, making the stock its 14th largest holding. Nuance Investments LLC’s holdings in Henry Schein were worth $21,335,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. Artisan Partners Limited Partnership lifted its position in shares of Henry Schein by 5.7% in the 3rd quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after acquiring an additional 370,837 shares during the period. Invesco Ltd. lifted its position in shares of Henry Schein by 4.1% in the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock worth $314,043,000 after acquiring an additional 184,763 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Henry Schein by 6.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,596,168 shares of the company’s stock worth $172,304,000 after acquiring an additional 159,087 shares during the period. Ameriprise Financial Inc. lifted its position in shares of Henry Schein by 11.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock worth $167,453,000 after acquiring an additional 256,156 shares during the period. Finally, Snyder Capital Management L P lifted its position in shares of Henry Schein by 18.6% in the 3rd quarter. Snyder Capital Management L P now owns 1,334,364 shares of the company’s stock worth $88,562,000 after acquiring an additional 209,123 shares during the period. Institutional investors own 96.62% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on HSIC shares. Wall Street Zen downgraded Henry Schein from a “strong-buy” rating to a “buy” rating in a research report on Sunday, April 26th. Barrington Research set a $97.00 price objective on Henry Schein and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Mizuho cut their target price on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Citigroup initiated coverage on Henry Schein in a research report on Wednesday, April 15th. They set a “buy” rating and a $100.00 target price for the company. Finally, Leerink Partners restated a “market perform” rating on shares of Henry Schein in a research report on Monday, March 9th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $86.83.

Insider Buying and Selling at Henry Schein

In other Henry Schein news, Director Kurt P. Kuehn sold 2,844 shares of Henry Schein stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the transaction, the director owned 15,420 shares in the company, valued at approximately $1,217,563.20. The trade was a 15.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas C. Popeck sold 1,355 shares of Henry Schein stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the completion of the transaction, the chief executive officer owned 86,182 shares of the company’s stock, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.89% of the company’s stock.

Henry Schein Price Performance

Henry Schein stock opened at $77.45 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75. The company has a market capitalization of $8.82 billion, a PE ratio of 23.40, a price-to-earnings-growth ratio of 1.47 and a beta of 0.82. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $89.29. The business has a 50 day simple moving average of $74.70 and a 200 day simple moving average of $75.93.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The business had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter last year, the company earned $1.15 EPS. Henry Schein’s revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, sell-side analysts forecast that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.